ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Management and Research"
DOI: 10.2147/cmar.s226410
Abstract: Background Acquired tamoxifen resistance is one of the major barriers to the successful treatment of breast cancer. Recently, overexpression of ERα36 was demonstrated to be a potential mechanism for the generation of acquired tamoxifen resistance.… read more here.
Keywords: expression; tamoxifen resistant; cancer; breast cancer ... See more keywords